ADAP logo

Adaptimmune Therapeutics (ADAP) Cash From Operations

Annual CFO

-$140.88 M
+$889.00 K+0.63%

December 31, 2023

Summary

Performance

1-Year Change

+0.63%

3-Year Change

-162.88%

5-Year Change

-34.96%

15-Year Change

-159.38%

ADAP Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

9.22%
ADAP annual cash flow from operations is higher than 9.22% of companies in Healthcare sector

High & Low

All-time High

$36.84 M
ADAP annual cash flow from operations is currently -482.46% below its historical high of $36.84 million

3-Year Low

-$141.77 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ADAP previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 6, 2025
ADAP next annual earnings announcement is scheduled for Mar 6, 2025

OtherADAPcash flowmetrics:

Annual CFI

$176.54 M
ADAP annual cash flow from investing activities is $176.54 million

Annual CFF

$880.00 K
ADAP annual cash flow from financing activities is $880.00 thousand

Annual FCF

-$145.76 M
ADAP annual free cash flow is -$145.76 million

Annual CAPEX

$4.88 M
ADAP annual capital expenditures is $4.88 million

Quarterly CFO

-$54.45 M
-$101.85 M-214.88%

September 30, 2024

Summary

Performance

3-Month Change

-214.88%

1-Year Change

-70.43%

3-Year Change

-20.47%

5-Year Change

-83.91%

ADAP Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

5.41%
ADAP quarterly cash flow from operations is higher than 5.41% of companies in Healthcare sector

High & Low

All-time High

$133.93 M
ADAP quarterly cash flow from operations is currently -140.66% below its historical high of $133.93 million

3-Year Low

-$54.45 M
ADAP quarterly cash flow from operations is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ADAP previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 6, 2025
ADAP next earnings announcement is scheduled for Mar 6, 2025

OtherADAPcash flowmetrics:

Quarterly CFI

-$66.02 M
ADAP quarterly cash flow from investing activities is -$66.02 million

Quarterly CFF

$25.00 M
ADAP quarterly cash flow from financing activities is $25.00 million

Quarterly FCF

-$54.89 M
ADAP quarterly free cash flow is -$54.89 million

Quarterly CAPEX

$435.00 K
ADAP quarterly capital expenditures is $435.00 thousand

TTM CFO

-$53.68 M
-$9.29 M-20.93%

September 30, 2024

Summary

Performance

3-Month Change

-20.93%

1-Year Change

+60.4%

3-Year Change

+64.78%

5-Year Change

+52.29%

ADAP TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

27.25%
ADAP TTM cash flow from operations is higher than 27.25% of companies in Healthcare sector

High & Low

All-time High

$10.73 M
ADAP TTM cash flow from operations is currently -600.31% below its historical high of $10.73 million

3-Year Low

-$141.77 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ADAP previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 6, 2025
ADAP next earnings announcement is scheduled for Mar 6, 2025

OtherADAPcash flowmetrics:

TTM CFI

$1.08 M
ADAP TTM cash flow from investing activities is $1.08 million

TTM CFF

$78.82 M
ADAP TTM cash flow from financing activities is $78.82 million

TTM FCF

-$56.05 M
ADAP TTM free cash flow is -$56.05 million

TTM CAPEX

$2.37 M
ADAP TTM capital expenditures is $2.37 million

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ADAP Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+0.6%-70.4%+60.4%
3 y3 years-162.9%-20.5%+64.8%
5 y5 years-35.0%-83.9%+52.3%

ADAP Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-1413.1%+0.6%-140.7%at low-600.3%+62.1%
5 y5-year-1413.1%+0.6%-140.7%at low-600.3%+64.8%
alltimeall time-482.5%+0.6%-140.7%at low-600.3%+64.8%

Adaptimmune Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$54.45 M(-214.9%)
-$53.68 M(+20.9%)
Jun 2024
-
$47.40 M(-248.4%)
-$44.39 M(-67.3%)
Mar 2024
-
-$31.95 M(+117.7%)
-$135.55 M(-3.8%)
Dec 2023
-$140.88 M(-0.6%)
-$14.68 M(-67.5%)
-$140.88 M(+13.5%)
Sep 2023
-
-$45.16 M(+3.2%)
-$124.16 M(-2.4%)
Jun 2023
-
-$43.76 M(+17.4%)
-$127.16 M(+2.0%)
Mar 2023
-
-$37.28 M(-1925.8%)
-$124.65 M(-12.1%)
Dec 2022
-$141.77 M(-1421.4%)
$2.04 M(-104.2%)
-$141.77 M(+1334.5%)
Sep 2022
-
-$48.16 M(+16.7%)
-$9.88 M(+42.7%)
Jun 2022
-
-$41.25 M(-24.2%)
-$6.92 M(-341.4%)
Mar 2022
-
-$54.40 M(-140.6%)
$2.87 M(-73.3%)
Dec 2021
$10.73 M(-120.0%)
$133.93 M(-396.3%)
$10.73 M(-107.0%)
Sep 2021
-
-$45.20 M(+43.7%)
-$152.41 M(+23.4%)
Jun 2021
-
-$31.46 M(-32.4%)
-$123.53 M(+5.6%)
Mar 2021
-
-$46.54 M(+59.3%)
-$116.99 M(+118.3%)
Dec 2020
-$53.59 M(-52.4%)
-$29.22 M(+79.1%)
-$53.59 M(+45.2%)
Sep 2020
-
-$16.32 M(-34.5%)
-$36.90 M(-26.5%)
Jun 2020
-
-$24.91 M(-247.8%)
-$50.19 M(-15.6%)
Mar 2020
-
$16.86 M(-234.6%)
-$59.45 M(-47.2%)
Dec 2019
-$112.51 M
-$12.53 M(-57.7%)
-$112.51 M(-14.5%)
Sep 2019
-
-$29.61 M(-13.3%)
-$131.66 M(+42.9%)
DateAnnualQuarterlyTTM
Jun 2019
-
-$34.17 M(-5.6%)
-$92.12 M(-1.3%)
Mar 2019
-
-$36.20 M(+14.3%)
-$93.31 M(-10.6%)
Dec 2018
-$104.39 M(+92.2%)
-$31.68 M(-418.8%)
-$104.39 M(+11.0%)
Sep 2018
-
$9.94 M(-128.1%)
-$94.06 M(+3.9%)
Jun 2018
-
-$35.36 M(-25.2%)
-$90.51 M(+23.7%)
Mar 2018
-
-$47.28 M(+121.4%)
-$73.16 M(+34.7%)
Dec 2017
-$54.31 M(+12.8%)
-$21.36 M(-258.3%)
-$54.31 M(+77.6%)
Sep 2017
-
$13.49 M(-174.9%)
-$30.59 M(-48.5%)
Jun 2017
-
-$18.01 M(-36.7%)
-$59.44 M(+2.6%)
Mar 2017
-
-$28.44 M(-1300.0%)
-$57.93 M(+20.3%)
Dec 2016
-$48.17 M(+166.7%)
$2.37 M(-115.4%)
-$48.17 M(-4.7%)
Sep 2016
-
-$15.37 M(-6.8%)
-$50.54 M(+42.6%)
Jun 2016
-
-$16.49 M(-11.7%)
-$35.44 M(+87.1%)
Mar 2016
-
-$18.68 M(+6903.7%)
-$18.95 M(+717.4%)
Dec 2015
-$18.06 M(-39.1%)
-
-
Sep 2015
-
-$266.70 K(-87.0%)
-$2.32 M(-84.7%)
Jun 2015
-$29.67 M(-180.5%)
-
-
Dec 2014
-
-$2.05 M(-84.3%)
-$15.15 M(+15.7%)
Sep 2014
-
-$13.10 M
-$13.10 M
Jun 2014
$36.84 M(-574.4%)
-
-
Jun 2013
-$7.77 M
-
-

FAQ

  • What is Adaptimmune Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Adaptimmune Therapeutics?
  • What is Adaptimmune Therapeutics annual CFO year-on-year change?
  • What is Adaptimmune Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Adaptimmune Therapeutics?
  • What is Adaptimmune Therapeutics quarterly CFO year-on-year change?
  • What is Adaptimmune Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Adaptimmune Therapeutics?
  • What is Adaptimmune Therapeutics TTM CFO year-on-year change?

What is Adaptimmune Therapeutics annual cash flow from operations?

The current annual CFO of ADAP is -$140.88 M

What is the all time high annual CFO for Adaptimmune Therapeutics?

Adaptimmune Therapeutics all-time high annual cash flow from operations is $36.84 M

What is Adaptimmune Therapeutics annual CFO year-on-year change?

Over the past year, ADAP annual cash flow from operations has changed by +$889.00 K (+0.63%)

What is Adaptimmune Therapeutics quarterly cash flow from operations?

The current quarterly CFO of ADAP is -$54.45 M

What is the all time high quarterly CFO for Adaptimmune Therapeutics?

Adaptimmune Therapeutics all-time high quarterly cash flow from operations is $133.93 M

What is Adaptimmune Therapeutics quarterly CFO year-on-year change?

Over the past year, ADAP quarterly cash flow from operations has changed by -$22.50 M (-70.43%)

What is Adaptimmune Therapeutics TTM cash flow from operations?

The current TTM CFO of ADAP is -$53.68 M

What is the all time high TTM CFO for Adaptimmune Therapeutics?

Adaptimmune Therapeutics all-time high TTM cash flow from operations is $10.73 M

What is Adaptimmune Therapeutics TTM CFO year-on-year change?

Over the past year, ADAP TTM cash flow from operations has changed by +$81.87 M (+60.40%)